Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accomplish, accomplished, accomplishing, acquiescence, adjudicated, anniversary, annum, ARB, Arizona, asminority, assetimpairmentsincluded, assetsand, attachment, availablecash, Bainbridge, bankrupt, barred, Bayer, Bexxar, bid, binder, binding, Biogen, Biopharma, biosimilar, bisplatinate, BLA, bonded, branch, brostallicin, carryover, chain, CHMP, CIA, CMO, Commissione, compelling, contacted, convenience, covenant, creation, CSP, custodian, custody, Debtor, decide, decided, defray, delisted, depository, deprive, diagnostic, diffuse, discrepancy, diversion, DNA, dossier, doublet, entry, EORTC, explanatory, expressly, extraordinary, Favrille, feel, fill, FIT, flat, follicular, foreclosure, formation, Frederick, GE, Genetic, Genitope, Genmab, Genta, GlaxoSmithKline, grace, groove, heavily, hematopoietic, highest, Histological, HITT, hundred, Ibritumomab, Idec, indemnification, indemnify, inInternal, inpreferred, insolvency, insolvent, Inspector, instance, instruction, involuntary, isotope, justification, landscape, le, leveraged, liposarcoma, LLC, LP, Malinckrodt, mark, Medicaid, merged, mezzanine, MTA, multiplied, municipal, myxoid, Nazionale, nineteen, noncontrolling, Nordion, outpatient, owner, paragraph, partnership, pattern, petition, PharmaMar, PHSA, physical, platform, positron, possession, potency, preceding, promissory, put, qualitative, quickly, quotient, radioimmunotherapeutic, radioimmunotherapy, radioisotope, radiopharmaceutical, ratification, reaction, rebrand, recurring, relief, rendered, resolution, retitled, retroactively, risky, sample, sarcoma, sBLA, scan, Schering, Scottsdale, script, Secondaria, SEER, seizure, SM, Societ, soft, sophisticated, Southern, speed, stabilize, stayed, stronger, sublicense, succeeding, switching, symptom, synergy, synthetic, Tang, TGen, thousand, throughput, Titoli, Tiuxetan, tomography, Topic, travel, trustee, Tucson, unamortized, uncollectible, uncontested, undeveloped, unfamiliar, unique, unreserved, untreated, user, warranty, wider, writ, Zevalin
Removed:
accrual, aggressively, answered, antibody, ASCO, asserting, auditing, aware, bladder, body, bore, BSHAP, cisplatin, conceived, confirmed, construed, cytarabine, damaged, dexamethasone, diarrhea, disclose, discovered, discovering, ejection, enabling, encouraging, ESHAP, esophageal, etoposide, extended, fluctuation, forming, fraction, furnish, GAAP, gastric, gastrointestinal, hematologic, Hematologica, hematuria, Hoffman, infrequent, infusional, invalid, journal, lacked, largely, left, LIBOR, Link, LLP, loan, marker, marketable, Max, metastatic, methylprednisolone, Mexico, modifying, Munich, netted, optimization, optionee, PanGenex, patented, periodic, Phil, purportedly, recurrent, relation, requiring, retaining, Roche, sought, spread, subjected, successor, systemic, targeting, thereunder, thornton, threshold, tolerated, typical, underwriter, unlawful, variant, variation, ventricular, Vermont
Filing tables
Filing exhibits
- 10-K Annual report
- 12.1 Statement Re: Computation of Ratio of Earnings to Fixed Charges
- 21.1 Subsidiaries of the Registrant
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of Chief Executive Officer
- 31.2 Certification of Chief Financial Officer
- 32 Certification of Chief Executive Officer and Chief Financial Officer
Related press release
CTIC similar filings
Filing view
External links
Exhibit 21.1
Subsidiaries of Cell Therapeutics, Inc.
CTI Corporate Development, Inc., an Oregon Corporation, Systems Medicine LLC, a Delaware Limited Liability Company, and Aequus Biopharma, Inc., a Washington Corporation.
The above paragraph includes all subsidiaries of Cell Therapeutics, Inc.